← Eichor
Condition: Recurrent Advanced Malignant Solid Neoplasm Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent Advanced Malignant Solid Neoplasm

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06687070APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 2 · 35 location(s) · Apollomics Inc. · NCT03175224Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
Phase 2 · 7 location(s) · Centre Leon Berard · NCT02029001Immunotherapy for the Treatment of Advanced Solid Tumor
Phase 1/Phase 2 · 1 location(s) · Tongji Hospital · NCT03658785Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
Phase 2 · 1 location(s) · Fudan University · NCT06914674Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid
NA · 1 location(s) · Mayo Clinic · NCT07174661Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · 483 location(s) · National Cancer Institute (NCI) · NCT05564377A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma
Phase 2 · 35 location(s) · Day One Biopharmaceuticals, Inc. · NCT04775485Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom T
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT04693468A Study of PYX-201 in Advanced Solid Tumors
Phase 1 · 29 location(s) · Pyxis Oncology, Inc · NCT05720117A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Phase 1/Phase 2 · 2 location(s) · Spago Nanomedical AB · NCT06184035CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 · 9 location(s) · Context Therapeutics Inc. · NCT06756035Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05039801Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
NA · 4 location(s) · Fred Hutchinson Cancer Center · NCT04515810A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Phase 1 · 16 location(s) · IDEAYA Biosciences · NCT07277413Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT05059678Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors
Phase 1/Phase 2 · 12 location(s) · A2 Biotherapeutics Inc. · NCT06051695Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and So
Phase 1 · 1 location(s) · Lantern Pharma Inc. · NCT06132503A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 102 location(s) · DualityBio Inc. · NCT05150691Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Phase 1 · 1 location(s) · Chinese PLA General Hospital · NCT05631886Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Sol
Phase 1/Phase 2 · 1 location(s) · OHSU Knight Cancer Institute · NCT06320405Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or M
Phase 4 · 4 location(s) · University Hospital, Basel, Switzerland · NCT06408688A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid
Phase 1 · 11 location(s) · Exelixis · NCT06952010Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285Studying TAK-243 in Patients With Advanced Cancer
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06223542A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Phase 1 · 38 location(s) · Eli Lilly and Company · NCT06465069
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.